Phathom Pharmaceuticals, Inc. Common Stock (PHAT) is a publicly traded Healthcare sector company. As of September 21, 2026, PHAT trades at $7.48 with a market cap of $605.14M and a P/E ratio of -2.48. PHAT moved -3.35% today. Year to date, PHAT is -54.91%; over the trailing twelve months it is -36.34%. Its 52-week range spans $2.21 to $18.31. Analyst consensus is strong buy with an average price target of $19.29. Rallies surfaces PHAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for PHAT combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $7.48 |
| Market Cap | $605.14M |
| P/E Ratio | -2.48 |
| EPS | $-3.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.31 |
| 52-Week Low | $2.21 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $175.11M |
| Net Income | $-221.25M |
| Gross Margin | 87.09% |
7 analysts cover PHAT: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.29.